Medical News

Bristol-Myers, Gilead Work on New Combo HIV Pill

October 27, 2011

Bristol-Myers Squibb Co. and Gilead Sciences Inc. announced Wednesday a deal to develop and sell a once-a-day HIV pill that combines a popular protease inhibitor (PI) with a boosting agent.

Under the plan, Bristol-Myers will formulate, manufacture, and sell the combination treatment. The pill includes Bristol-Myers' PI Reyataz and Gilead's cobicistat, which works to raise HIV drug levels in the blood by blocking an enzyme that breaks down drugs. Gilead is currently conducting mid- and late-stage human trials of the combination pill in newly diagnosed patients.

The two companies already work together on the three-drug pill Atripla, the first approved once-a-day HIV drug; it is now prescribed to more than half of new HIV patients. Atripla includes Sustiva, made by Bristol-Myers, and Gilead's Viread and Emtriva.

Combination pills have become the foundation of HIV treatment, as they make regimen adherence much less difficult.

Back to other news for October 2011

Adapted from:
Associated Press
10.26.2011; Linda A. Johnson

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.